Clinical study of different administration methods of mouse nerve growth factor in the treatment of occupational noise-induced deafness
10.3760/cma.j.cn115455-20200827-01152
- VernacularTitle:鼠神经生长因子不同给药方式治疗职业性噪声聋的临床研究
- Author:
Ning SU
;
Lihui YANG
- From:
Chinese Journal of Postgraduates of Medicine
2021;44(3):220-224
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the therapeutic effect of drum room injection and intramuscular injection of rat nerve growth factor on occupational noise-induced deafness (ONID).Methods:Sixty-six patients with ONID treatment from January 2018 to December 2019 in the People′s Hospital of Liaoning Province were divided into control group and study group by random number table, with 33 patients in each group. On the basis of conventional treatment, all patients in the study group were injected with 20 μg rat nerve growth factor in the drum room, and each ear was injected once every other day. The control group was given intramuscular injection of rat nerve growth factor 20 μg per day, and the patients in two groups were treatment for 28 d. The hearing threshold of left and right whisper frequency of the two groups were compared. The improvement of tinnitus, dizziness, headache, insomnia, other symptoms and the scores of Hamilton Depression Scale (HAMD) was compared between the two groups.Results:Before treatment, the hearing thresholds of left whisper frequency and right whisper frequency in two groups had no significant differences ( P>0.05). After treatment, the hearing thresholds of left whisper frequency and right whisper frequency in the study group were significantly lower than those in the control group: (23.8 ± 4.2) dB/HL vs. (34.5 ± 3.9) dB/HL, (23.2 ± 4.4) dB/HL vs. (35.9 ± 5.1) dB/HL, and there were statistical differences ( P<0.05). After treatment, tinnitus and dizziness symptom improvement rate in the study group were higher than those in the control group: 93.3% (28/30) vs. 72.4% (21/29), 15/17 vs. 8/16, and there were statistically significant differences ( χ2 = 4.584 and 5.705, P<0.05). There was no statistically significant difference in the improvement rate of headache and insomnia symptoms between 2 groups ( P>0.05). The total effective rate in the treatment group was significantly higher than that in the control group: 90.9% (30/33) vs. 69.7% (23/33), and there was statistical difference ( χ2 = 4.694, P<0.05). After treatment, the scores of HAMD of 2 groups were significantly decreased, and the scores of HAMD in the study group was lower than that in control group: (8.46 ± 3.13) scores vs. (10.55 ± 3.83) scores, and there was statistical difference ( P<0.05). The incidence of total adverse reactions between 2 groups had no significant difference ( P>0.05). Conclusions:The injection of mouse nerve growth factor into drum room to treat ONID can effectively improve the hearing level of patients, alleviate tinnitus and dizziness symptoms and improve adverse mood without obvious adverse reactions.
